[
  {
    "ts": null,
    "headline": "Dividend Stocks Aren’t Just for Income Investors. Here’s Another Reason to Buy Them.",
    "summary": "Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.",
    "url": "https://finnhub.io/api/news?id=dfd99a0a140f72c1d85ea4a80eadba25ceaacce5a2a9bb8aaf7bb76bae40b08c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761259860,
      "headline": "Dividend Stocks Aren’t Just for Income Investors. Here’s Another Reason to Buy Them.",
      "id": 137216061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.",
      "url": "https://finnhub.io/api/news?id=dfd99a0a140f72c1d85ea4a80eadba25ceaacce5a2a9bb8aaf7bb76bae40b08c"
    }
  },
  {
    "ts": null,
    "headline": "Roche in ongoing discussions with US government over drug pricing, CEO says",
    "summary": "US pricing pressures come amid aggressive deal-making moves by Roche to bolster its internal pipeline.",
    "url": "https://finnhub.io/api/news?id=424723d14bc28b261f5d02e555bd3f1c9c36870ec15e479c5bcdf54fd2938fa0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761238412,
      "headline": "Roche in ongoing discussions with US government over drug pricing, CEO says",
      "id": 137198221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US pricing pressures come amid aggressive deal-making moves by Roche to bolster its internal pipeline.",
      "url": "https://finnhub.io/api/news?id=424723d14bc28b261f5d02e555bd3f1c9c36870ec15e479c5bcdf54fd2938fa0"
    }
  },
  {
    "ts": null,
    "headline": "Medpace Holdings’ Good Quarter Is Another Sign Biotech Is Back",
    "summary": "The strong earnings report from  Medpace Holdings  which runs clinical trials to test biotech companies’ new drugs, offers more evidence that the biotech sector is on the rebound.  Medpace said late Wednesday that it had $789 million in new orders in the third quarter, up about 49% from the year-ago period.  Its clinical trial backlog was up 2.5% from the 2024 third quarter, signaling an improving environment for the small- and midsize biotechs that make up most of its clients.",
    "url": "https://finnhub.io/api/news?id=17c2827d6dd571dd12ab5e9d7948f62a40a094dd413791cf65ea78c290aa0602",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761232500,
      "headline": "Medpace Holdings’ Good Quarter Is Another Sign Biotech Is Back",
      "id": 137198222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The strong earnings report from  Medpace Holdings  which runs clinical trials to test biotech companies’ new drugs, offers more evidence that the biotech sector is on the rebound.  Medpace said late Wednesday that it had $789 million in new orders in the third quarter, up about 49% from the year-ago period.  Its clinical trial backlog was up 2.5% from the 2024 third quarter, signaling an improving environment for the small- and midsize biotechs that make up most of its clients.",
      "url": "https://finnhub.io/api/news?id=17c2827d6dd571dd12ab5e9d7948f62a40a094dd413791cf65ea78c290aa0602"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
    "url": "https://finnhub.io/api/news?id=ae6afbec598fa70842fd7d7bc158de8d879174b55ffb1b2beab79012399c52e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761230340,
      "headline": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
      "id": 137197694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
      "url": "https://finnhub.io/api/news?id=ae6afbec598fa70842fd7d7bc158de8d879174b55ffb1b2beab79012399c52e7"
    }
  },
  {
    "ts": null,
    "headline": "The Other Reason to Buy Dividend Stocks",
    "summary": "Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.",
    "url": "https://finnhub.io/api/news?id=caa7a8ccd7e8b3e168a822d5872814a693b3ddbe562f1a8e184862f2e73cdf81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761221340,
      "headline": "The Other Reason to Buy Dividend Stocks",
      "id": 137197799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.",
      "url": "https://finnhub.io/api/news?id=caa7a8ccd7e8b3e168a822d5872814a693b3ddbe562f1a8e184862f2e73cdf81"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: The Prime Target In The Obesity Gold Rush",
    "summary": "Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.",
    "url": "https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761213917,
      "headline": "Viking Therapeutics: The Prime Target In The Obesity Gold Rush",
      "id": 137196743,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241752128/image_2241752128.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.",
      "url": "https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a"
    }
  },
  {
    "ts": null,
    "headline": "United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall",
    "summary": "The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l",
    "url": "https://finnhub.io/api/news?id=c71cd6e181f0deeeb69881f06ea43c4f632fd7742a51c44af85236f556c4c0bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761212280,
      "headline": "United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall",
      "id": 137197962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l",
      "url": "https://finnhub.io/api/news?id=c71cd6e181f0deeeb69881f06ea43c4f632fd7742a51c44af85236f556c4c0bc"
    }
  },
  {
    "ts": null,
    "headline": "Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue",
    "summary": "The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.",
    "url": "https://finnhub.io/api/news?id=e42785f0eb8f598b01cfb3e294109eadec999bde7d15ec3d47cfc78cb96833fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761211440,
      "headline": "Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue",
      "id": 137198226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.",
      "url": "https://finnhub.io/api/news?id=e42785f0eb8f598b01cfb3e294109eadec999bde7d15ec3d47cfc78cb96833fb"
    }
  }
]